严露萱,朱爱琴

帕金森病（PD）是一种神经退行性疾病，主要影响运动系统，其特征为多巴胺能神经元的丧失及α-突触核蛋白的聚集。尽管PD的发病机制已有部分被阐明，但仍未完全明确。近年来，遗传学的研究揭示表观遗传可能在PD的发生与进展中发挥关键作用。本文综述主要探讨了DNA甲基化在PD发病机制中所扮演的复杂角色。我们强调，靶向干预DNA甲基化在调节与PD相关的信号通路方面具有潜在的治疗价值，同时呼吁进一步拓展这一极有前景的帕金森病治疗策略。

帕金森病；DNA甲基化；表观遗传修饰

[1] Jankovic J.Parkinson's disease:clinical features and diagnosis[J].J Neurol Neurosurg Psychiatry,2008,79(4):368-76. [2] Sharma T,Kaur D,Grewal A K,et al.Therapies modulating insulin resistance in Parkinson's disease:A cross talk[J].Neurosci Lett, 2021,749:135754. [3] Dorsey E R,Sherer T,Okun M S,et al.The Emerging Evidence of the Parkinson Pandemic[J].J Parkinsons Dis,2018,8(s1):S3-s8. [4] Dickson D W.Parkinson's disease and parkinsonism:neuropathology[J].Cold Spring Harb Perspect Med,2012,2(8). [5] Li Y.Modern epigenetics methods in biological research[J].Methods,2021,187:104-13. [6] Zhang L,Lu Q,Chang C.Epigenetics in Health and Disease[J].Adv Exp Med Biol,2020,1253:3-55. [7] Laird P W.Principles and challenges of genomewide DNA methylation analysis[J].Nat Rev Genet,2010,11(3):191-203. [8] Mattei A L,Bailly N,Meissner A.DNA methylation:a historical perspective[J].Trends Genet,2022,38(7):676-707. [9] Watt F,Molloy P L.Cytosine methylation prevents binding to DNA of a HeLa cell transcription factor required for optimal expression of the adenovirus major late promoter[J].Genes Dev,1988,2(9):1136-43. [10] CoppedèF.One-Carbon Metabolism and Alzheimer's Disease:The DNA Methylation Hypothesis[M].Advances in Genome Science, 2013. [11] Polymeropoulos M H,Lavedan C,Leroy E,et al.Mutation in the alpha-synuclein gene identified in families with Parkinson's disease[J]. Science,1997,276(5321):2045-7. [12] Krüger R,Kuhn W,Müller T,et al.Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease[J].Nat Genet, 1998,18(2):106-8. [13] Zarranz J J,Alegre J,Gómez-Esteban J C,et al.The new mutation,E46K,of alpha-synuclein causes Parkinson and Lewy body dementia[J].Ann Neurol,2004,55(2):164-73. [14] Chartier-Harlin M C,Kachergus J,Roumier C,et al.Alpha-synuclein locus duplication as a cause of familial Parkinson's disease[J]. Lancet,2004,364(9440):1167-9. [15] Singleton A B,Farrer M,Johnson J,et al.alpha-Synuclein locus triplication causes Parkinson's disease[J].Science,2003,302(5646):841. [16] Jowaed A,Schmitt I,Kaut O,et al.Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains[J].J Neurosci,2010,30(18):6355-9. [17] Matsumoto L,Takuma H,Tamaoka A,et al.CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson's disease[J].PLoS One,2010,5(11):e15522. [18] Desplats P,Spencer B,Coffee E,et al.Alpha-synuclein sequesters Dnmt1 from the nucleus:a novel mechanism for epigenetic alterations in Lewy body diseases[J].J Biol Chem,2011,286(11):9031-7. [19] Schmitt I,Evert B O,Sharma A,et al.The Alpha-Synuclein Gene(SNCA)is a Genomic Target of Methyl-CpG Binding Protein 2(MeCP2)-Implications for Parkinson's Disease and Rett Syndrome[J].Mol Neurobiol,2024. [20] De Mena L,Cardo L F,Coto E,et al.No differential DNA methylation of PARK2 in brain of Parkinson's disease patients and healthy controls[J].Mov Disord,2013,28(14):2032-3. [21] Navarro-Sánchez L,Águeda-Gómez B,Aparicio S,et al.Epigenetic Study in Parkinson's Disease:A Pilot Analysis of DNA Methylation in Candidate Genes in Brain[J].Cells,2018,7(10). [22] Barrachina M,Ferrer I.DNA methylation of Alzheimer disease and tauopathy-related genes in postmortem brain[J].J Neuropathol Exp Neurol,2009,68(8):880-91. [23] Coupland K G,Mellick G D,Silburn P A,et al.DNA methylation of the MAPT gene in Parkinson's disease cohorts and modulation by vitamin E in vitro[J].Mov Disord,2014,29(13):1606-14. [24] Su X,Chu Y,Kordower J H,et al.PGC-1αPromoter Methylation in Parkinson's Disease[J].PLoS One,2015,10(8):e0134087. [25] Zheng L,Bernard-Marissal N,Moullan N,et al.Parkin functionally interacts with PGC-1αto preserve mitochondria and protect dopaminergic neurons[J].Hum Mol Genet,2017,26(3):582-98. [26] St-Pierre J,Drori S,Uldry M,et al.Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators[J].Cell,2006,127(2):397-408. [27] Kaut O,Schmitt I,Wüllner U.Genome-scale methylation analysis of Parkinson's disease patients'brains reveals DNA hypomethylation and increased mRNA expression of cytochrome P450 2E1[J]. Neurogenetics,2012,13(1):87-91. [28] Masliah E,Dumaop W,Galasko D,et al.Distinctive patterns of DNA methylation associated with Parkinson disease:identification of concordant epigenetic changes in brain and peripheral blood leukocytes[J].Epigenetics,2013,8(10):1030-8. [29] Go R C P,Corley M J,Ross G W,et al.Genome-wide epigenetic analyses in Japanese immigrant plantation workers with Parkinson's disease and exposure to organochlorines reveal possible involvement of glial genes and pathways involved in neurotoxicity[J].BMC Neurosci,2020,21(1):31. [30] Sinha D,D'silva P.Chaperoning mitochondrial permeability transition:regulation of transition pore complex by a J-protein, DnaJC15[J]. Cell Death Dis,2014,5(3):e1101. [31] Kochmanski J,Kuhn N C,Bernstein A I.Parkinson's disease-associated,sex-specific changes in DNA methylation at PARK7(DJ-1), SLC17A6(VGLUT2),PTPRN2(IA-2β),and NR4A2(NURR1)in cortical neurons[J].NPJ Parkinsons Dis,2022,8(1):120. [32] Shendelman S,Jonason A,Martinat C,et al.DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation[J].PLoS Biol,2004,2(11):e362. [33] Dashtipour K,Tafreshi A,Adler C,et al.Hypermethylation of Synphilin-1,Alpha-Synuclein-Interacting Protein(SNCAIP)Gene in the Cerebral Cortex of Patients with Sporadic Parkinson's Disease[J].Brain Sci,2017,7(7). [34] Alvarez-Castelao B,Castaño J G.Synphilin-1 inhibits alpha-synuclein degradation by the proteasome[J].Cell Mol Life Sci, 2011,68(15):2643-54. [35] Young J I,Sivasankaran S K,Wang L,et al.Genome-wide brain DNA methylation analysis suggests epigenetic reprogramming in Parkinson disease[J].Neurol Genet,2019,5(4):e342. [36] Stafa K,Trancikova A,Webber P J,et al.GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1[J].PLoS Genet,2012,8(2):e1002526. [37] Xiong Y,Yuan C,Chen R,et al.ArfGAP1 is a GTPase activating protein for LRRK2:reciprocal regulation of ArfGAP1 by LRRK2[J].J Neurosci,2012,32(11):3877-86. [38] Xu Z,Li X.DNA Methylation in Neurodegenerative Disorders[J].Current Geriatrics Reports,2012,1(4):199-205. [39] Cheng Y,Xie N,Jin P,et al.DNA methylation and hydroxymethylation in stem cells[J].Cell Biochem Funct,2015,33(4):161-73. [40] Sun Z,Kantor B,Chiba-Falek O.Neuronal-type-specific epigenome editing to decrease SNCA expression:Implications for precision medicine in synucleinopathies[J].Mol Ther Nucleic Acids,2024,35(1):102084. [41] Guhathakurta S,Kim J,Adams L,et al.Targeted attenuation of elevated histone marks at SNCA alleviatesα-synuclein in Parkinson's disease[J].EMBO Mol Med,2021,13(2):e12188.

点击下载PDF